Clinical trials: Fibrosis
Cystic Fibrosis, Dysbiosis
Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
The study will assess if administration of high-dose vitamin D and a commonly used prebiotic (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal functions in Cystic Fibrosis with the…
- Trial name
- NCT04118010
- Testing
- Vitamin D3, Inulin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Liver Cirrhosis and Hepatoma., Gastric Variceal Bleeding
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic treatment.
- Trial name
- GVO-nadolol (NCT00567216)
- Testing
- Nadolol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Cystic Fibrosis
Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations
Cystic fibrosis pulmonary exacerbations (CF PEx) vary greatly in their severity, their pathogens, and their treatment responses.
- Trial name
- NCT04354038
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Jewish Health
Liver Cirrhosis
Lean Mass Evaluation of Cirrhotic Patients With Ascites With the Use DXA
Malnutrition due to liver disease is common, however, their detection is difficult. The parameters used for nutritional assessment in clinical practice have limited use in this patient population.
- Trial name
- BCECPA (NCT02421848)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).
- Trial name
- NCT06460506
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 50 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
Keloid, Stem Cell
Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
This study is a double-blind randomized controlled trial (RCT) examining the effect of intralesional injection of umbilical cord-derived mesenchymal stem cells (UC-MSC), umbilical cord-derived conditioned medium (UC-CM), or…
- Trial name
- NCT05887804
- Testing
- umbilical cord-derived mesenchymal stem cells (UC-MSC), umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM), Triamcinolone Acetonide (TA)
- Where
- Indonesia
- Volunteers
- 24 people
- Sponsor
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Idiopathic Pulmonary Fibrosis, Activity, Motor
Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis Patients
The Londrina Activities of Daily Living Protocol was first developed for Chronic Obstructive Pulmonary Disease patients and was found to be valid and reliable, but there is no validity and reliability study of the Londrina…
- Trial name
- NCT06049004
- Testing
- Activities of Daily Living Protocol
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Izmir Katip Celebi University
Cystic Fibrosis
PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis
Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an increasingly common finding, and the lack of an evidenced-based approach to treatment of NTM disease has been identified as one of the…
- Trial name
- PATIENCE (NCT02419989)
- Where
- 19 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Jewish Health
Biliary Cirrhosis, Primary
Family Studies in Primary Biliary Cirrhosis (PBC)
Primary biliary cirrhosis (PBC) is a chronic liver disease primarily affecting middle age women. It is characterized by immune-mediated damage to cells lining the tiny bile ducts within the liver.
- Trial name
- NCT00242125
- Where
- Canada
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto
Cystic Fibrosis Related Diabetes, Hyperglycaemia
Investigating the Relationship Between Glycemia and Sleep in Adults With Cystic Fibrosis-Related Diabetes
The goal of this at-home, remote study is to understand the relationship between blood sugars and sleep in adults living with Cystic Fibrosis Related Diabetes (CFRD).
- Conditions
- Cystic Fibrosis Related Diabetes, Hyperglycaemia, Insomnia, Cardiometabolic Diseases
- Trial name
- NCT06700889
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
HIV, Hepatitis C
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone.
- Conditions
- HIV, Hepatitis C, Liver Fibrosis
- Trial name
- NCT01231685
- Testing
- Raltegravir, Ritonavir-boosted protease inhibitor
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Human Papillomavirus Infection
HPV Vaccination in Women With Cystic Fibrosis
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19…
- Trial name
- VACCIN-HPV-MUC (NCT03265743)
- Testing
- Self-report Written Questionnaire
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Hospices Civils de Lyon
Gastroesophageal Varices, Cirrhosis
The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices
The purpose of the study is to compare the effect of HVPG-guided individualized therapy and non-HVPG guided traditional therapy in cirrhotic patients for secondary prophylaxis.
- Trial name
- NCT02638415
- Testing
- HVPG-guided therapy, routine therapy, Carvedilol
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Zhongshan Hospital
Focal Fibrosis
Decreased T1 Times and Impaired Myocardial Contractility in Anabolic Androgenic Steroids Users
Anabolic androgenic steroids (AAS) abuse may have a toxic on myocardium that could lead to cardiac alterations. Clinical cases reported myocardial fibrosis in AAS users.
- Trial name
- NCT03862235
- Testing
- Cardiovascular Magnetic Resonance, Transthoracic echocardiography
- Where
- Brazil
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
This study will examine whether five drugs (pravastatin, Losartan, Zileuton, N-acetylcysteine and erythromycin) used together can slow the course of pulmonary fibrosis (scarring of the lung tissue) in patients with…
- Conditions
- Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency
- Trial name
- NCT00467831
- Testing
- Losartan, Zileuton, N-Acetylcysteine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pruritus
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
- Trial name
- NCT04950127
- Testing
- Linerixibat
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 238 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
- Trial name
- NCT07036029
- Testing
- NAL ER
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevi Therapeutics